Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology.
Saved in:
| Title: | Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology. |
|---|---|
| Authors: | Mercuri FA; ENA Respiratory, Melbourne, VIC, Australia.; These authors contributed equally., White S; ENA Respiratory, Melbourne, VIC, Australia.; These authors contributed equally., McQuilten HA; ENA Respiratory, Melbourne, VIC, Australia., Lemech C; Scientia Clinical Research Ltd, Randwick, NSW, Australia.; Prince of Wales Clinical School, UNSW, Sydney, NSW, Australia., Mynhardt S; Resolutum Global Pty Ltd, VIC, Australia., Hari R; Scientia Clinical Research Ltd, Randwick, NSW, Australia., Zhang P; Griffith Biostatistics Unit, Griffith Health, Griffith University Gold Coast Campus, QLD, Australia., Kruger N; ENA Respiratory, Melbourne, VIC, Australia., McLachlan G; ENA Respiratory, Melbourne, VIC, Australia., Miller BE; ENA Respiratory, Melbourne, VIC, Australia., West NP; School of Pharmacy and Medical Science and the Institute for Biomedicine and Glycomics, Griffith University, Gold Coast Campus, QLD, Australia., Tal-Singer R; ENA Respiratory, Melbourne, VIC, Australia., Demaison C; ENA Respiratory, Melbourne, VIC, Australia. |
| Source: | ERJ open research [ERJ Open Res] 2024 Dec 09; Vol. 10 (6). Date of Electronic Publication: 2024 Dec 09 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: European Respiratory Society Country of Publication: England NLM ID: 101671641 Publication Model: eCollection Cited Medium: Print ISSN: 2312-0541 (Print) Linking ISSN: 23120541 NLM ISO Abbreviation: ERJ Open Res Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
